Epstein-Barr Virus and Cytomegalovirus Coinfection in Egyptian COVID-19 Patients

Abstract Background Reactivation of herpesviruses such as Epstein–Barr virus (EBV) and cytomegalovirus (CMV) in COVID-19 patients reported in many studies in different countries during the pandemic. We aimed to measure prevalence of this coinfection in Egyptian COVID-19 patients with elevated liver enzymes and its relation to the severity and the outcome of COVID-19 infection in those patients. Methods A cross-sectional study was carried out on 110 COVID-19 patients with elevated liver enzymes regardless the severity of COVID-19 disease. All patients were subjected to medical history, clinical examination, laboratory investigations, high-resolution computed tomography chest (HRCT chest). Epstein-Barr virus (EBV) and Human cytomegalovirus (HCMV) were determined by VCA IgM and CMV IgM respectively by enzyme linked immunosorbent assay (Elisa). Results Of the included 110 patients with COVID-19 illness, 5 (4.5%) were Epstein-Barr virus seropositive and 5 (4.5%) were Human cytomegalovirus seropositive. Regarding the symptoms, the incidence of fever in the EBV & CMV seropositive group was apparently higher than that in the EBV & CMV seronegative group. In lab tests, the platelets and albumin of EBV & CMV seropositive group decreased more significantly than EBV & HCMV seronegative group, and serum ferritin, D-dimer and c-reactive protein show higher values in seropositive group than in seronegative group but not statistically significant. Seropositive group had received higher doses of steroids than seronegative group. The median of hospital stay in seropositive group was (15 days) nearly double that of seronegative group with statistically significant difference between both groups. Conclusion Coinfection of EBV and CMV in COVID-19 Egyptian has no effect on the disease severity or the clinical outcome of the disease. But Those patients had higher hospital stay duration.